Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

NCT07713901 | Enrolling By Invitation

• 2 other identifiers: NN2211-8841U1111-1341-5652
• Study Type: observational
• Target: 93,600,000
• Locations: 1 country
• Sites: 1

Brief Summary

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Conditions

Medullary Thyroid Carcinoma

Outcome Measures

Primary Outcomes (1)

• Time to first occurence of Medullary Thyroid Carcinoma (MTC)

  Measured in number of days.

  From day 1 up to 15 years

Study Arms (4)

Long-acting GLP-1 RA Exposed Cohort

Participants will be eligible for inclusion in this cohort if they have at least one dispensed prescription for a LA GLP-1 RA therapy during the study patient selection period.

Other: No treatment given

T2D Active Comparator 1 Cohort

Participants will be included in this cohort if they fill at least one dispensed prescription for SGLT2 or DPP-4 inhibitors during the study patient selection period with no evidence of SGLT2 or DPP-4 inhibitors and without LA GLP-1 RA use during the prior 12-month lookback period.

Other: No treatment given

T2D Active Comparator 2 Cohort

Participants will be included in this cohort if they fill at least one dispensed prescription for any antidiabetic medications (including SGLT2 or DPP-4 inhibitors), other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.

Other: No treatment given

Overweight/Obesity Active Comparator Cohort

Participants will be included in this cohort if they fill at least one dispensed prescription for anti-obesity medications, other than LA GLP-1 RA therapies during the study patient selection period with no evidence of the cohort qualifying medication during the prior 12-month lookback period.

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

Long-acting GLP-1 RA Exposed Cohort; Overweight/Obesity Active Comparator Cohort; T2D Active Comparator 1 Cohort; T2D Active Comparator 2 Cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adults aged 18 years and older in the United States who are receiving routine treatment for type 2 diabetes or weight management and are identified utilizing real-world data (RWD).

You may qualify if:

• years or older during the year of index (date of qualifying medication)
• In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
• ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
• No evidence of cohort qualifying medication during 12-month before the index date
• Reside in the US, including the District of Columbia (DC) during the study period
• No missing values for year of birth

You may not qualify if:

• Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

IQVIA

Parsippany, New Jersey, 07054, United States

Location

MeSH Terms

Conditions

Carcinoma, Medullary

Condition Hierarchy (Ancestors)

Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Ductal, Lobular, and Medullary; Neoplasms, Nerve Tissue

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2026
• First Posted: July 20, 2026
• Study Start: December 31, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: July 20, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)